| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Sep, 2024 | Jun, 2024 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -1,820 | 110 | 0 | -600 | -960 |
| Net Income Growth | -1,754.55% | unch | +100.00% | +37.50% | unch |
Liminatus Pharma Inc Cl A (LIMN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Liminatus Pharma LLC operates as a clinical-stage immuno-oncology company which develops novel cancer therapies. Liminatus Pharma LLC is based in LA Palma, California.